# 2026-08104: DEA Bans Risky Synthetic Drug MDMB-4en-PINACA Immediately

2026-08104, Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2026-04-24, effective 2026-04-27; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-08104
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08104
- Title: Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
- Type: Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 21958
- Published: 2026-04-24
- Effective: 2026-04-27
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Bans Risky Synthetic Drug MDMB-4en-PINACA Immediately

## Summary

Starting April 27, 2026, the DEA is officially putting MDMB-4en-PINACA—a powerful and risky chemical—into Schedule I, the strictest drug category. This means anyone making, selling, or using it will face serious legal rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer from this dangerous substance.

## Abstract

With the issuance of this final rule, the Drug Enforcement Administration places methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H- indazole-3-carboxamido)butanoate (other name: MDMB-4en-PINACA), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle MDMB-4en-PINACA.

## Effects PRIA read

- MDMB-4en-PINACA placed in Schedule I: cost, high. On April 27, 2026, the Drug Enforcement Administration permanently placed MDMB-4en-PINACA (including its salts and isomers) in Schedule I of the Controlled Substances Act. That means manufacture, distribution, import/export, research, or possession of MDMB-4en-PINACA without proper authorization is…
- DEA Registration and Compliance Required: cost, low. Anyone who handles MDMB-4en-PINACA (manufacture, distribute, import/export, research, chemical analysis, or possession) must register with DEA and comply with Schedule I rules starting April 27, 2026. Registered handlers must follow specific controls including security, labeling and packaging rules…
- Research Allowed With Schedule I Registration: cost, low. Placement in Schedule I does not prohibit bona fide research on MDMB-4en-PINACA, but researchers must apply for and obtain Schedule I researcher registration through DEA's researcher registration program to conduct such work. The rule notes researchers wishing to study Schedule I substances may app…
- DEA Certifies Minimal Small-Entity Impact: benefit, low. DEA certified that this final rule will not have a significant economic impact on a substantial number of small entities. DEA stated it identified one supplier in relevant industries (already DEA-registered) and found no evidence of significant diversion from legitimate suppliers.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-08104 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i)
- [2026-08104 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-24/pdf/2026-08104.pdf)

## Related
- [Previous: 2026-08103, One-Page Document on Passenger Rights](https://policyrisk.com/federal-register/2026-08103)
- [Next: 2026-08106, Airworthiness Directives; Pratt & Whitney Engines](https://policyrisk.com/federal-register/2026-08106)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08104 (as of 2026-06-11).
